

Protonix® I.V. (pantoprazole) - Expanded indication

- On August 12, 2024, the <u>FDA approved</u> Pfizer's <u>Protonix I.V. (pantoprazole)</u>, for treatment of gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) for up to 10 days in adults and up to 7 days in pediatric patients 3 months and older.
 - Protonix I.V. was previously approved for short-term treatment (7 to 10 days) of adult patients with GERD and a history of EE.
- Protonix I.V. is also approved for treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome in adults.
- The approval of Protonix I.V. for the expanded indication was supported by evidence from
 adequate and well-controlled studies of intravenous and oral pantoprazole sodium in adults and
 oral pantoprazole sodium in pediatric patients, with additional pharmacokinetic and safety data of
 intravenous pantoprazole in pediatric patients 1 year of age and older and oral pantoprazole in
 pediatric patients 3 months of age and older.
- The recommended dose of Protonix I.V. for the treatment of pediatric patients 3 months of age and older is based on age and actual body weight.
- Refer to the Protonix I.V. drug label for complete dosing and administration recommendations for both pediatric and adult patients.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.